## SUMMARY

**[0005]** In one aspect, the present disclosure refers to use of valbenazine, or an isotopic variant thereof, or a pharmaceutically acceptable salt of valbenazine or an isotopic variant thereof, in the manufacture of a medicament for the treatment of dyskinesia due to cerebral palsy in a patient in need thereof. Also provided is a method of treating dyskinesia due to cerebral palsy in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of valbenazine, or an isotopic variant thereof, or a pharmaceutically acceptable salt of valbenazine or an isotopic variant thereof. In some examples, the valbenazine, or an isotopic variant thereof, or a pharmaceutically acceptable salt of valbenazine or an isotopic variant thereof, is administered via a titration scheme that comprises the up-titration of the valbenazine, or an isotopic variant thereof, or a pharmaceutically acceptable salt of valbenazine or an isotopic variant thereof, over a period of no more than about six weeks until an optimized dose is administered.

**[0006]** These and other aspects of the disclosure will be apparent upon reference to the following detailed description. To this end, various references are set forth herein which describe in more detail certain background information, procedures, compounds, and/or compositions, and are each hereby incorporated by reference in their entirety.

## BRIEF DESCRIPTION OF THE FIGURES

**[0007]** FIG. 1 shows a schematic of the study design. Randomization will be stratified by age group (6 to 11 years, 12 to 17 years, and18 to 70 years) and stable concomitant botulinum toxin regimen (yes/no) at baseline (Day 1). Valbenazine dose for pediatric patients < 50 kg starts at 20 mg/day. Valbenazine dose for pediatric patients ≥ 50 kg and adults starts at 40 mg/day. For patients who do not tolerate a dose increase, one dose level reduction is allowed from the highest titrated dose during each treatment period. A follow-up visit will occur 2 weeks after the last dose of study treatment. Patients who discontinue study treatment early during the double-blind treatment period should remain in the study to complete Week 14 study assessments. PBO=placebo; R=randomization; VBZ=valbenazine.

## DETAILED DESCRIPTION

**[0008]** In the following description, certain specific details are set forth in order to provide a thorough understanding of various embodiments. However, one skilled in the art will understand that the invention may be practiced without these details. In other instances, well-known structures have not been shown or described in detail to avoid unnecessarily obscuring descriptions of the embodiments. Unless the context requires otherwise, throughout the specification and claims which follow, the word “comprise” and variations